The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Breakthrough Technology Meets High-Touch Patient Care
Measuring dark adaptation speed with the AdaptDx Pro™ can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.
Latest News & Upcoming EventsView More
Just by adding dark adaptation testing to your practice, doctors can do more for patients at risk of developing AMD. By Julie Rodman, OD, MSc, FAAO.
New Annual Report Demonstrates How Dark Adaptation Makes AMD Management Easy, Accurate, and Profitable
MacuLogix announces the recent publication of “Practical Opportunities in AMD Management,” the fourth in a series of annual reports aimed at reducing avoidable vision loss.
Theia helps eye care professionals like Mary Miller, CPOT, take care of her patients – which is her favorite part as a technician at Kirman Eye.